February 2026 in “Pharmaceuticals” KRDQN effectively predicts adverse drug reactions with high accuracy and clear explanations.
13 citations
,
September 2022 in “Materials & design” The new patch for treating mouth sores releases medicine slowly, sticks well, and helps healing without the side effects of current creams.
February 2024 in “Journal of the European Academy of Dermatology and Venereology” Baricitinib is effective and safe for long-term use in severe alopecia areata, improving hair regrowth and quality of life with few side effects.
4 citations
,
February 2019 in “PubMed” Clascoterone may be an effective topical treatment for hair loss.
13 citations
,
April 2019 in “International journal of molecular sciences” Acyzol could help treat conditions caused by zinc deficiency.
5 citations
,
January 2016 in “BLDE University Journal of Health Sciences” Kasisa Bhasma is safer and nontoxic compared to Shodhita Kasisa.
1 citations
,
August 2021 in “Journal of Investigative Dermatology” ASLAN004 was safe and well-tolerated, supporting further development for treating certain diseases.
2 citations
,
September 2024 in “Expert Opinion on Drug Metabolism & Toxicology” Ritlecitinib is an effective new treatment for Alopecia Areata.
December 2013 in “Nursing2023” The FDA approved a new breast cancer treatment, found flu shots may reduce heart risks, questioned the safety of fast-tracked drug approvals, showed statins don't help with certain pneumonia, and approved a new dementia imaging agent.
1 citations
,
June 2022 in “JAMA” Baricitinib, a medication taken by mouth, was effective in regrowing hair for people with severe hair loss.
January 2024 in “Pharmaceutical journal/The pharmaceutical journal” Ritlecitinib can help about 14,000 people with severe hair loss.
24 citations
,
November 1978 in “JAMA” Valproic acid is effective for various seizures, but may cause temporary side effects like drowsiness and stomach issues.
July 2025 in “Journal of the European Academy of Dermatology and Venereology”
July 2003 in “Pediatrics in review” In 2001, the FDA approved 12 new drugs for children to treat allergies, asthma, ADHD, birth control, and other conditions.
4 citations
,
October 2024 in “American Journal of Clinical Dermatology” Ritlecitinib improved hair regrowth and emotional well-being in some alopecia areata patients.
3 citations
,
April 2025 in “American Journal of Clinical Dermatology” Baricitinib is generally safe for long-term use in treating severe alopecia areata.
April 2024 in “Journal of asthma and allergy” Abrocitinib effectively treated severe atopic dermatitis and mild alopecia areata in a 12-year-old boy after dupilumab failed.
5 citations
,
March 2020 in “Thoracic Cancer” CT-707 is effective and safe for treating certain Chinese lung cancer patients.
Baricitinib helps keep hair, eyebrows, and eyelashes regrown for 3 years in most people with severe hair loss.
March 2024 in “EMBO molecular medicine” Antiviral drugs, especially daclatasvir, may be a new treatment for a rare skin disease, improving survival and reducing symptoms in mice.
July 2025 in “Journal of Investigative Dermatology” TRIV-509 quickly improves skin barrier and cell health in atopic dermatitis.
September 2023 in “International Journal of Applied Pharmaceutics” The formulated gel is a promising treatment for alopecia areata.
1 citations
,
June 2001 in “Annals of Internal Medicine” The conclusion is that maintaining blinding in clinical trials is crucial for reliable results.
18 citations
,
February 2025 in “Drug Delivery and Translational Research” The microneedle patches effectively treat allergic conjunctivitis with controlled, sustained release of medication.
14 citations
,
August 2018 in “Journal of Pharmaceutical and Biomedical Analysis” April 2023 in “Journal of Investigative Dermatology” A new treatment for hair loss shows promise with fewer side effects.
March 2025 in “International Journal For Multidisciplinary Research” Computational techniques can improve drug development for treating certain conditions.
2 citations
,
December 2021 in “Korean Journal of Clinical Pharmacy” 23 citations
,
October 2021 in “AAPS PharmSciTech”
1 citations
,
July 2025 in “Frontiers in Endocrinology” ApoBDs, once seen as waste, are now viewed as potential tools for disease treatment and tissue repair.